Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL295685

CCCC[n+]1cccc(C)c1.O=S(=O)([O-])C(F)(F)F

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 7/20 0.50
KDM4E B2RXH2 1/20 0.43
APAF1 O14727 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
RAD52 P43351 1/20 0.43
BLM P54132 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL29396207 1.00 KCNH2 (0.50) KCNH2KDM4EAPAF1ALDH1A1LMNA
Trifluoromethanesulfonic Acid SCHEMBL30329835 0.96 KCNH2 (0.52) KCNH2LMNARAD52
Trifluoromethanesulfonic Acid SCHEMBL30212841 0.96 KCNH2 (0.52) KCNH2LMNARAD52
Trifluoromethanesulfonic Acid SCHEMBL30212901 0.96 KCNH2 (0.52) KCNH2LMNARAD52
Trifluoromethanesulfonic Acid SCHEMBL23004140 0.96 KCNH2 (0.52) KCNH2LMNARAD52
Trifluoromethanesulfonic Acid SCHEMBL23004225 0.96 KCNH2 (0.52) KCNH2LMNARAD52
Trifluoromethanesulfonic Acid SCHEMBL23004387 0.96 KCNH2 (0.52) KCNH2LMNARAD52
Trifluoromethanesulfonic Acid SCHEMBL23004549 0.96 KCNH2 (0.52) KCNH2LMNARAD52
Trifluoromethanesulfonic Acid SCHEMBL14990400 0.96 KCNH2 (0.52) KCNH2LMNARAD52
Trifluoromethanesulfonic Acid SCHEMBL28251929 0.96 KCNH2 (0.52) KCNH2LMNARAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210395906-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY CUSTOMARRAY INC (US) 2021-12-23 US claimed
CN-107847867-B Composite membranes having improved performance and/or durability and methods of use thereof 3M创新有限公司 2021-06-25 CN claimed
CN-107427758-B Separation using ionic liquid solvents 切弗朗菲利浦化学公司 2020-11-20 CN claimed
US-20200164319-A1 COMPOSITE MEMBRANES WITH IMPROVED PERFORMANCE AND/OR DURABILITY AND METHODS OF USE 3M INNOVATIVE PROPERTIES COMPANY 2020-05-28 US claimed
US-20200030748-A1 COMPOSITE MEMBRANES WITH IMPROVED PERFORMANCE AND/OR DURABILITY AND METHODS OF USE 3M INNOVATIVE PROPERTIES COMPANY 2020-01-30 US claimed
US-10478778-B2 Composite membranes with improved performance and/or durability and methods of use 3M INNOVATIVE PROPERTIES COMPANY (US) 2019-11-19 US claimed
US-20180154311-A1 COMPOSITE MEMBRANES WITH IMPROVED PERFORMANCE AND/OR DURABILITY AND METHODS OF USE 3M INNOVATIVE PROPERTIES COMPANY 2018-06-07 US claimed
US-20150133711-A1 Separations With Ionic Liquid Solvents CHEVRON PHILLIPS CHEMICAL COMPANY LP 2015-05-14 US claimed
EP-1658268-B1 MIXTURES OF IONIC LIQUIDS WITH LEWIS ACIDS NOVARTIS AG (CH) 2014-02-12 EP claimed
US-20130341561-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY CUSTOMARRAY, INC. (US) 2013-12-26 US claimed
EP-1869061-A2 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY Combimatrix Corporation (US) 2007-12-26 EP claimed
EP-1805206-A2 ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE Combimatrix Corporation (US) 2007-07-11 EP claimed
US-20070034513-A1 Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array COMBIMATRIX CORPORATION 2007-02-15 US claimed
WO-2007006418-A1 IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2007-01-18 WO claimed
WO-2006131234-A1 COSMETIC COMPOSITIONS COMPRISING IONIC LIQUIDS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2006-12-14 WO claimed
WO-2006105037-A2 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY COMBIMATRIX CORPORATION (US) 2006-10-05 WO claimed
WO-2006031814-A2 ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE COMBIMATRIX CORPORATION (US) 2006-03-23 WO claimed
US-20060054511-A1 Electrochemical deblocking using a hydrazine derivative CUSTOMARRAY, INC. 2006-03-16 US claimed
US-20050150383-A1 Facilitated transport membranes for an alkene Hydrocarbon separation KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY 2005-07-14 US claimed
EP-1552875-A1 Facilitated transport membranes for an alkene hydrocarbon separation Korea Institute of Science and Technology (KR) 2005-07-13 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395906-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY DNMT1, DNASE1, DNPEP KCNH2 484/4885KDM4E 4183/4885APAF1 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.